BioPharma Credit PLC (LSE:BPCR) lends to life sciences companies and returns income to shareholders through quarterly dividends declared in US cents. This article explains the business, the 2026 Dividend timetable and how the dividend relates to reported Earnings and cash.
Business Overview
The company's objective is to deliver long-term Shareholder returns mainly through sustainable income from exposure to life sciences debt. It invests primarily in Debt secured by royalties or other cash flows from sales of approved life sciences products, using senior secured loans, convertible notes and purchased payments. Dividends are declared in US currency, with shareholders able to elect to receive sterling.
For the year ended 31 December 2025, Net Income was 11.40 US cents per share, compared with 9.99 US cents in 2024, and NAV per share rose to 101.92 US cents from 99.63 US cents. During 2025 the company invested US$301.3m in new and existing positions and received US$616.6m in repayments. Cash stood at US$422.3m at the year end, equal to 36.7% of net assets. It also repurchased 56.8 million shares, or 4.14% of the shares in issue, for US$50.3m under its discount control mechanism.
In the first half of 2026, NAV per share was US$1.0148, compared with US$1.0192 at the end of 2025, and the return after finance costs and taxation was US$50.4m. The company repurchased a further 7.0 million shares during the period.
Dividend Record
The board targets a base dividend of 7 US cents per share each year, paid in quarterly instalments of at least 1.75 US cents, a minimum the company has met every quarter since 30 June 2018. When income exceeds the base level, the board may add special dividends. For 2025, dividends relating to the year's results were 9.95 US cents, compared with 10.18 US cents for 2024, above the 7 cent base.
The 2026 timetable has been as follows. A dividend declared on 10 February 2026 for the quarter ended 31 December 2025 totalled 3.20 US cents, comprising an ordinary 1.75 cents and a Special Dividend of about 1.45 cents. It went ex-dividend on 19 February, had a Record Date of 20 February and was paid on 20 March 2026. An Interim Dividend of 1.75 US cents for the quarter ended 31 March 2026 went ex-dividend on 30 April, had a record date of 1 May and was paid on 29 May 2026. A further 1.75 US cents for the quarter ended 30 June 2026 had a record date of 3 July and was paid on 31 July 2026.
The ex-dividend date is the first day on which new buyers no longer receive the next payment, the record date identifies registered holders, and the payment date is when cash is paid. By default dividends are paid in US dollars.
Dividend Cover and Sustainability
BioPharma Credit PLC (LSE:BPCR) earns income mainly from interest and royalty-linked payments, so the relevant comparison is net income per share against the dividend per share. For 2025, net income of 11.40 US cents compared with 9.95 US cents of dividends relating to that year, which indicates that income exceeded payments during the period.
Repayments of US$616.6m in 2025 exceeded new investments of US$301.3m, and a large cash balance gives the company capacity to fund new loans, buy back shares or pay special dividends. Special dividends are discretionary and tied to Loan repayments and income received, so they can vary from year to year, while the 1.75 cent ordinary quarterly amount provides the regular base.
Recent Developments
The annual financial report for 2025 was published on 24 March 2026. After the year end, the company amended its loan to UroGen on 26 February 2026, committed up to US$125m to Zenas BioPharma on 14 March 2026, provided US$50m of new debt to Paratek and sold 18 million Cytokinetics convertible notes. The chair will step down at the end of 2026, with Rolf Soderstrom succeeding.
The half-year report added further commitments, including a US$45m commitment to Kestra after the period end. On 10 November 2026 the company announced a new Investment of up to US$50m in CorMedix Inc..
Factors to Watch
Life sciences lending depends on product sales, regulatory approvals and the ability of borrowers to repay. Repayments from a single borrower can change the cash balance significantly, as seen when US$261.4m was received from one borrower on 23 December 2025.
Dividends are declared in US dollars, so sterling holders may see differences from Exchange Rate movements. Interest rates affect the return on new loans and the value of existing ones. The board has also used a discount control mechanism to repurchase shares, which affects the number of shares in issue and the per-share figures reported.
Key Insights
BioPharma Credit PLC (LSE:BPCR) pays a regular quarterly dividend of at least 1.75 US cents, supported by a base target of 7 US cents a year, and adds special dividends when income allows. The February 2026 payment of 3.20 US cents illustrates how a special element can sit on top of the ordinary amount.
The key measures to follow are net income per share, NAV per share, cash balances and the pace of loan repayments and new commitments, all of which are reported in the half-year and annual reports. Readers who understand the declaration, ex-dividend, record and payment sequence, and who check the currency of each figure, can interpret each announcement accurately and compare it with the company's stated policy.
Some background on the loan structures may help readers. A royalty-backed loan is repaid from a share of the sales of an approved product, so repayment timing depends on how quickly sales grow, while a convertible note combines interest with the right to convert into shares of the borrower. Purchased payments give the company the right to receive a defined stream of cash flows. Looking at 2025, repayments of US$616.6m, new investments of US$301.3m and share repurchases of US$50.3m all moved the balance sheet, and the 2026 figures should be read in the same way, alongside the stated dividend policy.






Please wait processing your request...